Canada markets open in 2 hours 20 minutes
  • S&P/TSX

    21,173.45
    -111.39 (-0.52%)
     
  • S&P 500

    4,574.79
    +8.31 (+0.18%)
     
  • DOW

    35,756.88
    +15.73 (+0.04%)
     
  • CAD/USD

    0.8055
    -0.0018 (-0.22%)
     
  • CRUDE OIL

    83.49
    -1.16 (-1.37%)
     
  • BTC-CAD

    73,378.06
    -5,177.30 (-6.59%)
     
  • CMC Crypto 200

    1,420.59
    -84.56 (-5.62%)
     
  • GOLD FUTURES

    1,790.60
    -2.80 (-0.16%)
     
  • RUSSELL 2000

    2,296.08
    -16.56 (-0.72%)
     
  • 10-Yr Bond

    1.6190
    0.0000 (0.00%)
     
  • NASDAQ futures

    15,522.00
    -23.00 (-0.15%)
     
  • VOLATILITY

    16.21
    +0.97 (+6.36%)
     
  • FTSE

    7,256.12
    -21.50 (-0.30%)
     
  • NIKKEI 225

    29,098.24
    -7.77 (-0.03%)
     
  • CAD/EUR

    0.6943
    -0.0014 (-0.20%)
     

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Iterum Therapeutics Plc of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 4, 2021 - ITRM

  • Oops!
    Something went wrong.
    Please try again later.
·3 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

New York, New York--(Newsfile Corp. - September 28, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:

To: All persons or entities who purchased or otherwise acquired securities of Iterum Therapeutics Plc ("Iterum") (NASDAQ: ITRM) between November 30, 2020 and July 23, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Northern District of Illinois. To get more information go to:

https://www.zlk.com/pslra-1/iterum-therapeutics-plc-loss-submission-form?prid=19945&wire=5

or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500. There is no cost or obligation to you.

Iterum Therapeutics Plc NEWS - ITRM NEWS

CASE DETAILS: According to the filed complaint: (i) the sulopenem New Drug Application ("NDA") lacked sufficient data to support approval for the treatment of adult women with urinary tract infections caused by designated susceptible microorganisms proven or strongly suspected to be nonsusceptible to a quinolone; (ii) accordingly, it was unlikely that the Food and Drug Administration would approve the sulopenem NDA in its current form; (iii) Defendants downplayed the severity of issues and deficiencies associated with the sulopenem NDA; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

WHAT THIS MEANS TO SHAREHOLDERS: If you suffered a loss in Iterum, you have until October 4, 2021 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

NO COST TO YOU: If you purchased Iterum securities between November 30, 2020 and July 23, 2021, you may be entitled to compensation without payment of any out-of-pocket costs or fees.

PROTECT YOUR FINANCIAL INTERESTS: Complete this brief submission form https://www.zlk.com/pslra-1/iterum-therapeutics-plc-loss-submission-form?prid=19945&wire=5 or call 212-363-7500 to discuss the case with Joseph E. Levi, Esq.

WHY LEVI & KORSINSKY: Levi & Korsinsky have a proven track record of winning cases worth hundreds of millions of dollars for shareholders over a 20-year period. We represent and fight for shareholders who have been wronged by corporations.

Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington, D.C. The Firm's Founding Partners, Joseph Levi and Eduard Korsinsky, have been representing shareholders and institutional clients for almost 20 years and have achieved remarkable results for clients in the U.S. and internationally. The firm, with more than 80 employees, is committed to fostering, cultivating and preserving a culture of diversity, equity and inclusion for employees and those that we represent. Our attorneys have extensive expertise representing investors in securities litigation with a track record of recovering hundreds of millions of dollars in cases. Levi & Korsinsky was ranked in Institutional Shareholder Services' ("ISS") SCAS Top 50 Report for 7 years in a row as a top securities litigation firm in the United States. The SCAS Top 50 Report identifies the top plaintiffs' securities law firms in the country, and year after year, ISS has recognized Levi & Korsinsky as a leading firm in the area of securities class action litigation.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/97951

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting